As an adjunctive treatment for T1D, tirzepatide (5 mg once weekly), a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, shows promise in improving glycemic control, reducing insulin dosage, and promoting weight control. This evidence concerns the gene GIP and type 1 diabetes mellitus.